LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements
23 juin 2023 08h30 HE
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CA, June 23, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“LIXTE” or the “Company”) announced today that it has received confirmation from The Nasdaq Stock...
Global Cancer Therapies Market Analysis Report 2022-2026: Chemotherapy & Targeted Therapy Lead the Global Cancer Therapies Market
05 août 2022 06h08 HE
|
Research and Markets
Dublin, Aug. 05, 2022 (GLOBE NEWSWIRE) -- The "Cancer Therapies - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Cancer Therapies Market...
Global RWE Oncology Market Research Report 2022
04 août 2022 07h23 HE
|
Research and Markets
Dublin, Aug. 04, 2022 (GLOBE NEWSWIRE) -- The "RWE Oncology Market by Component, Application, End User - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. The RWE...
Global Orphan Cancer Drug Market Report 2022-2028
12 juil. 2022 06h48 HE
|
Research and Markets
Dublin, July 12, 2022 (GLOBE NEWSWIRE) -- The "Global Orphan Cancer Drug Market, Drug Sales, Price & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. ...
LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market
12 avr. 2022 13h53 HE
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CA, April 12, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in...
Notable Announces Leadership Team Expansion
09 avr. 2020 14h03 HE
|
Notable Labs
SAN FRANCISCO, April 09, 2020 (GLOBE NEWSWIRE) -- Notable, a technology leader redefining cancer treatment through rapid drug development via a clinically validated platform, announced today its...
Notable Named To Fast Company’s Inaugural List Of The 50 Best Workplaces for Innovators
05 août 2019 10h45 HE
|
Notable Labs
SAN FRANCISCO, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Notable, which is redefining cancer treatment with a clinically validated platform that rapidly advances cancer drug development at a fraction of the...
Notable Announces $40M Series B Round to Fuel Development of Its Drug Discovery Platform for Personalized Oncology
16 juil. 2019 07h00 HE
|
Notable Labs
SAN FRANCISCO, July 16, 2019 (GLOBE NEWSWIRE) -- Notable, which is redefining cancer treatment with a clinically validated platform that rapidly advances cancer drug development at a fraction of the...
In Personalized Medicine Feasibility Study, Stanford Medical Center, With Partners Notable and Tempus, Able to Make Rapid Personalized Treatment Recommendations for 100 Percent of Blood Cancer Patients
15 avr. 2019 13h38 HE
|
Notable Labs
SAN FRANCISCO, April 15, 2019 (GLOBE NEWSWIRE) -- Notable, which is redefining cancer treatment with a clinically validated AI platform that rapidly advances cancer drug development at a fraction of...
Oncology Startup Notable Expands Leadership Team With New Chief Medical and Chief Development Officers
25 févr. 2019 11h00 HE
|
Notable Labs
FOSTER CITY, Calif., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Notable, which is redefining cancer treatment with a clinically validated platform that rapidly advances cancer drug development at a fraction...